Ticker Scorecard - ALNY Basics Company: Alnylam Pharmaceuticals, Inc. IPO Date: May 28, 2004 Sector: Healthcare Industry: Biotech Market Cap: $31.37B Activated in VL: True Average Daily Range Avg Daily Range: $1.56 | 2.21% Avg Daily Range (30 D): $4.26 | 1.72% Avg Daily Range (90 D): $3.70 | 1.43% Institutional Daily Volume Avg Daily Volume: .54M Avg Daily Volume (30 D): .44M Avg Daily Volume (90 D): .56M Trade Size Avg Trade Size (Sh.): 83 Avg Trade Size (Sh.) (30 D): 36 Avg Trade Size (Sh.) (90 D): 39 Institutional Trades Total Inst.Trades: 9,841 Avg Inst. Trade: $6.04M Avg Inst. Trade (30 D): $15.01M Avg Inst. Trade (90 D): $14.29M Avg Inst. Trade Volume: .05M Avg Inst. Trades (Per Day): 3 Market Closing Trades Avg Closing Trade: $10.22M Avg Closing Trade (30 D): $31.2M Avg Closing Trade (90 D): $30.84M Avg Closing Volume: 78.11K     News Nov 8, 2024 @ 7:35 PM Bristol-Myers Squibb Leads Biopharma Recovery With... Source: Vandana Singh Oct 18, 2024 @ 6:38 PM Avadel Obtains FDA Nod for Label Expansion Of Narc... Source: Zacks Oct 17, 2024 @ 5:44 PM Alnylam Stock Up on Cardiomyopathy Drug Regulatory... Source: Zacks Oct 7, 2024 @ 7:19 PM Exelixis Gains 20.7% in Three Months: Is This the ... Source: Zacks Oct 3, 2024 @ 4:00 PM Alnylam's Concedes Its Patent Infringement Case Ag... Source: Vandana Singh Financials   TTM Q3 2024 Q2 2024 Basic EPS $-2.62 $-.87 $-.13 Diluted EPS $-2.62 $-.87 $-.13 Revenue $ 2.09B $ 500.92M $ 659.83M Gross Profit $ 1.82B $ 418.94M $ 592.55M Net Income / Loss $ -332.26M $ -111.57M $ -16.89M Operating Income / Loss $ -188.13M $ -76.91M $ 48.61M Cost of Revenue $ 275.84M $ 81.98M $ 67.27M Net Cash Flow $ 67.29M $ 131.31M $ 286.47M PE Ratio